首页> 外文期刊>DNA and Cell Biology >Expression Profile Analysis of m6A RNA Methylation Regulators Indicates They Are Immune Signature Associated and Can Predict Survival in Kidney Renal Cell Carcinoma
【24h】

Expression Profile Analysis of m6A RNA Methylation Regulators Indicates They Are Immune Signature Associated and Can Predict Survival in Kidney Renal Cell Carcinoma

机译:M6A RNA甲基化调节剂的表达谱分析表明它们是免疫签名相关,可预测肾肾细胞癌中的存活

获取原文
获取原文并翻译 | 示例
           

摘要

N6-Methyladenosine (m6A) refers to the methylation modification occurring at the nitrogen-6 position of adenosine. Many human physiological processes such as modulation of spermatogenesis are caused by m6A RNA modifications. However, the relationship between m6A RNA methylation regulators and kidney renal clear cell carcinoma (KIRC) remains rarely investigated. This work aimed to explore the influence of m6A RNA methylation regulators in KIRC. We examined abnormally expressed m6A RNA methylation regulators among different clinicopathological features of KIRC. We recognized three subgroups (KIRC1, KIRC2, and KIRC3) with significant differences in overall survival through consensus clustering of m6A RNA methylation regulators. Surprisingly, KIRC2 displayed elevated immune activity, but high proportions of immune-inhibitory cells (Tregs and myeloid-derived suppressor cell) based on single-sample gene set enrichment analysis (ssGSEA) and CIBERSORT analysis. Moreover, the KIRC2 subgroup had the lowest tumor mutation burden levels and the highest expression levels of 80% (12/15) of co-inhibitory molecules. Next, correlation analysis indicated thatRBM15Bexpression was negatively correlated with multiple immune signatures, which was verified by ssGSEA and CIBERSORT analyses. Multiple immune-related and cancer-related pathways were enriched in the group with highRBM15Bexpression. Furthermore, a four-m6A RNA methylation regulator-based risk signature was constructed based on an ArrayExpress (E-MTAB-3267) dataset and confirmed in the The Cancer Genome Atlas (TCGA) testing cohort. In conclusion, our study successfully classified TCGA samples into three subgroups with different immune signatures, and suggested that the worse prognosis of KIRC2 is probably mediated by immune evasion. These findings will facilitate personalized immunotherapy in patients with KIRC. In addition, the risk score system was revealed as an independent prognostic marker that can predict survival in KIRC patients.
机译:N6甲基腺苷(m6A)是指发生在腺苷氮-6位的甲基化修饰。许多人类生理过程,如精子发生的调节,都是由m6A RNA修饰引起的。然而,m6A RNA甲基化调节因子与肾透明细胞癌(KIRC)之间的关系仍鲜有研究。本研究旨在探讨m6A RNA甲基化调节因子对KIRC的影响。我们检测了KIRC不同临床病理特征中异常表达的m6A RNA甲基化调节因子。我们通过m6A RNA甲基化调节因子的一致聚类,确认了三个亚组(KIRC1、KIRC2和KIRC3)在总体生存率上存在显著差异。令人惊讶的是,KIRC2显示出较高的免疫活性,但基于单样本基因集富集分析(ssGSEA)和CIBERSORT分析,免疫抑制细胞(Tregs和髓源性抑制细胞)的比例较高。此外,KIRC2亚组的肿瘤突变负荷水平最低,共抑制分子的表达水平最高,为80%(12/15)。其次,相关分析表明RBM15B表达与多种免疫特征呈负相关,这一点已通过ssGSEA和CIBERSORT分析得到验证。在RBM15B高表达组中,多种免疫相关和癌症相关途径得到了丰富。此外,基于ArrayExpress(E-MTAB-3267)数据集构建了一个基于四m6A RNA甲基化调节因子的风险特征,并在癌症基因组图谱(TCGA)测试队列中得到确认。总之,我们的研究成功地将TCGA样本分为三个具有不同免疫特征的亚组,并表明KIRC2预后较差可能是由免疫逃避介导的。这些发现将有助于KIRC患者的个性化免疫治疗。此外,风险评分系统是一个独立的预后指标,可以预测KIRC患者的生存率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号